Approval · Notice of Compliance 910 · 2001
ENTROPHEN: Notice of Compliance 910
Issued May 17, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 910
- Date
- May 17, 2001
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of 325 mg daily in the recommended dosage for unstable angina or previous myocardial infarction. revised indication for reducing the risk of recurrent transient ischemic attacks and for secondary prevention of atherothrombotic cerebral infarction to include women as well as men
- Therapeutic class
- Nonsteroidal anti-inflammatory, analgesic agent, platelet aggregation inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENTROPHEN | Not yet assigned | — |
Medicinal ingredients
- ACETYLSALICYLIC ACID 325 MG per TAB